---
category: news
title: "BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology"
excerpt: "Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of prostate cancer and is currently in Phase 2 clinical trials NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,"
publishedDateTime: 2022-04-19T11:13:00Z
originalUrl: "https://www.tmcnet.com/usubmit/2022/04/19/9584732.htm"
webUrl: "https://www.tmcnet.com/usubmit/2022/04/19/9584732.htm"
type: article

provider:
  name: TMCnet
  domain: tmcnet.com

topics:
  - AI in Healthcare
  - AI

secured: "qFhfzPfEFTiHYcEv37Aql6ptV0733qALFvk6M7dYQViSYOQDt+sAmoiXEWCYO1EUYKnTOrQoFFA5hEWcKZvl+WTjqkexh7ZTqtWk6qmPFoDdinyFiCWSlCzSrUovXWSdwn9cPKFwiPgt/SNbD5OdCnVFAlQSL0DYcyOf9a1gtqxT4wxmG2+p4a1lrqfxITdLqpsCL/wVoXMmhYBsDi0nK5454JxOqEDTMsnvgmhz8/cD06Uco2PEY+U7ETEY/XAwk7+KCOwxy0utej9qvhD6EUv8IPXQyNQ4Gdqga5UMhbR6V4vwxiO7OE2wExGKbB8i7N5RilF1aUKDKjZyK9+BOcLSa2GfylKdE/MayTOsuDM=;C2pFKJRCuMGtcHMjxGE0Vg=="
---

